The system showed highly efficient treatment ALI/ARDS by exploiting the advantages of these materials, including specific targeting to endothelial cells via CD31, the accurate identification of its molecular target Keap1 by the anti-inflammatory drug ORI, and the controlled release and few side effects of PLGA-PEG NPs (Figure 7). This evidence concerns the gene PECAM1 and acute respiratory distress syndrome.